- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06188975
Expanded Access to ABBV-CLS-484
December 18, 2023 updated by: Calico Life Sciences LLC
This is an expanded access program (EAP) for eligible participants.
This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency.
Availability will depend on territory eligibility.
A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Study Overview
Status
Available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
December 18, 2023
First Submitted That Met QC Criteria
December 18, 2023
First Posted (Estimated)
January 3, 2024
Study Record Updates
Last Update Posted (Estimated)
January 3, 2024
Last Update Submitted That Met QC Criteria
December 18, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- C24-918
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor Cancer
-
Novartis PharmaceuticalsTerminatedCancer | Solid Tumor | Advanced Solid TumorJapan
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
HC Biopharma Inc.RecruitingAdvanced Solid Tumor CancerChina
-
M.D. Anderson Cancer CenterRecruitingSolid Tumor | Advanced CancerUnited States
-
Strata OncologyMerck Sharp & Dohme LLC; Pfizer; Gilead SciencesTerminatedCancer | Advanced Solid TumorUnited States
-
STORM Therapeutics LTDCompletedCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Aptabio Therapeutics, Inc.RecruitingAdvanced Solid Cancer | Advanced Solid Tumor (Phase 1)South Korea
-
Shanghai Allink Biotherapeutics Co., Ltd.RecruitingAdvanced Solid Tumor | Advanced CancerAustralia, United States
-
Peking UniversityYingkai Saiwei(Beijing)Biotechnology Co., LtdRecruitingAdvanced Solid Tumor CancerChina
-
Sun Yat-sen UniversityRecruitingSolid Tumor | Advanced CancerChina
Clinical Trials on DRUG: ABBV-CLS-484
-
Merit E. Cudkowicz, MDCalico Life Sciences LLCCompleted
-
Calico Life Sciences LLCAbbVieCompletedHealthyUnited States
-
AbbVieNo longer availableVanishing White Matter | Cree Leukoencephalopathy
-
McGill University Health Centre/Research Institute...Active, not recruitingVanishing White Matter | Cree LeukoencephalopathyCanada
-
Calico Life Sciences LLCCalico Life Sciences LLCRecruitingAn Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter DiseaseVanishing White Matter DiseaseUnited States, Canada, Netherlands
-
AbbVieTerminatedMajor Depressive Disorder (MDD)United States
-
AbbVieCalico Life Sciences LLCTerminatedAmyotrophic Lateral Sclerosis | ALSUnited States, Canada
-
Calico Life Sciences LLCCalico Life Sciences LLCRecruitingAutosomal Dominant Polycystic Kidney DiseaseUnited States, Japan, Portugal, Spain, Netherlands, Australia, Belgium, France, Germany, South Korea, Italy
-
Calico Life Sciences LLCAbbVieCompletedHealthy VolunteerUnited States
-
AbbVieCompletedHealthy VolunteersUnited States